{"doi":"10.1093/oncolo/oyaf400","title":"NCI 10211: a phase II, single-arm study of berzosertib in combination with irinotecan in patients with advanced <i>TP53</i> mutant gastroesophageal cancer","abstract":"BACKGROUND: Mutations in TP53 are common in gastroesophageal cancer and portend a poor prognosis. Tumor cells with TP53 mutations increasingly rely on ataxia-telangiectasia and Rad3-related (ATR) protein to respond to and repair DNA damage induced by cytotoxic chemotherapy. We aimed to assess the efficacy of ATR inhibitor, berzosertib, with irinotecan in patients harboring TP53-mutated, metastatic gastroesophageal cancer. METHODS: NCI 10211 is a phase II trial that enrolled patients with TP53-mutated, unresectable or metastatic gastroesophageal adenocarcinoma to receive berzosertib with irinotecan on day 1, 15 in 28-day cycles. Initially, patients who had progressed on at least 1 prior line of therapy were enrolled which was later amended to at least 2 prior lines of therapy. The primary outcome was objective response rate (ORR), and secondary outcomes included progression-free survival (PFS) and overall survival (OS). Nine patients underwent biopsy for correlative studies, which included assay evaluation of γH2AX, NBS1, and KAP1 p-Ser 824 expression. RESULTS: Of the 17 patients enrolled, 16 were evaluable for the primary endpoint of ORR. The ORR was 0%, disease control rate (DCR) of 56.2%, median PFS (mPFS) of 4.01 months, and median OS (mOS) of 6.21 months. The study did not meet its primary endpoint. The most common treatment-related adverse events were nausea (52.9%), anemia (41.2%), diarrhea (41.2%), and lymphopenia (41.2%) without any unexpected adverse events. CONCLUSION: This novel combination of ATR inhibitor berzosertib with irinotecan did not lead to objective responses in patients with TP53-mutated, advanced gastroesophageal adenocarcinoma. The combination regimen was well tolerated without unexpected adverse events. This trial was registered with ClinicalTrials.gov (NCT03641313).","journal":"The Oncologist","year":2025,"id":584012,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9528,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT03641313"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":865055,"name":"Shannon Stockton","orcid":"0000-0003-2799-663X","position":1,"is_corresponding":false},{"id":984543,"name":"Heloisa P. Soares","orcid":"0000-0002-5185-2583","position":2,"is_corresponding":false},{"id":531649,"name":"Farshid Dayyani","orcid":"0000-0002-4970-5189","position":3,"is_corresponding":false},{"id":848455,"name":"Anwaar Saeed","orcid":"0000-0001-8024-9401","position":4,"is_corresponding":false},{"id":460876,"name":"Edward Kim","orcid":"0000-0002-8660-7465","position":5,"is_corresponding":false},{"id":427876,"name":"Ning Jin","orcid":"0000-0003-4280-8764","position":6,"is_corresponding":false},{"id":1496921,"name":"George Yacoub","orcid":null,"position":7,"is_corresponding":false},{"id":901609,"name":"Vaia Florou","orcid":"0000-0001-5558-753X","position":8,"is_corresponding":false},{"id":333195,"name":"Gregory D. Ayers","orcid":null,"position":9,"is_corresponding":false},{"id":1496494,"name":"Bella S. Guerrouahen","orcid":"0000-0003-4124-4389","position":10,"is_corresponding":false},{"id":379370,"name":"Alejandro Contreras","orcid":"0000-0001-6668-823X","position":11,"is_corresponding":false},{"id":629898,"name":"Liqing Li","orcid":"0000-0001-8297-309X","position":12,"is_corresponding":false},{"id":403213,"name":"Katherine V. Ferry‐Galow","orcid":null,"position":13,"is_corresponding":false},{"id":1496495,"name":"Steven Gore","orcid":"0009-0004-5227-4502","position":14,"is_corresponding":false},{"id":393145,"name":"Satya Das","orcid":"0000-0002-7625-1039","position":15,"is_corresponding":false},{"id":44878,"name":"Jordan Berlin","orcid":"0000-0001-7571-2385","position":16,"is_corresponding":false},{"id":1401507,"name":"Margaret C. Wheless","orcid":null,"position":0,"is_corresponding":true}],"reference_count":34,"raw_metadata":null,"created_at":"2026-07-19T02:59:07.970345Z","pmid":"41335461","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}